{"nct_id":"NCT02284568","title":"A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo","status":"COMPLETED","status_verified_date":"2022-03","start_date":"2015-01-12","start_date_type":"ACTUAL","primary_completion_date":"2017-05-04","primary_completion_date_type":"ACTUAL","completion_date":"2017-10-01","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["TEVA"]}